Efficiency of management of patients with irritable bowel syndrome with constipation and autoimmune thyroiditis with hypothyroidism using rifaximin

Abstract

Abstract. Background. Irritable bowel syndrome (IBS) is a common gastrointestinal sign of gut-brain axis disorder, which occurs with abdominal pain, bloating and abnormal bowel motility, and may be divided onto subtypes: with prevalence of constipation (IBS-C), diarrhea and mixed. Autoimmune thyroiditis (AIT) is the most prevalent endocrine disorder diagnosed in young patients, which can often coexist with IBS and influence its clinical course. Small intestinal bacterial overgrowth (SIBO) is usually registered in both disorders. SIBO treatment can improve the course of IBS. The purpose of the study is to assess the efficiency of additional use of rifaximin in treating patients with IBS-C and AIT with hypothyroidism.